ASCO 2017: Expanding the Actionable Landscape: Bladder Cancer Genomics - Introduction

Chicago, IL (OncToday.com) Dr. McConkey gave a most interesting introductory talk to the topic of bladder cancer genomics research. He pointed out the current ongoing genomic revolution in bladder cancer, consisting of completion of large scale genomic projects such as The Cancer Genome Atlas (TCGA), discovery of the basal and luminal subtypes of bladder cancer, extensive research in DNA damage and repair mutations and correlation to neo-antigens and overall mutational burden.
Read more ...

ASCO 2017: Cancer predisposing germline mutations in patients with urothelial cancer of the renal pelvis, ureter and bladder.

Chicago, IL (OncToday.com) Heritable genes in urothelial cancers (UC) have not been studied extensively, except for the mismatch-repair pathway (MMR) (e.g. MSH2) typically associated with primary UC involving the renal pelvis/ureter (Lynch syndrome). According to epidemiologic studies, 30% of UC have some heritable fraction.
Read more ...

ASCO 2017: DNA damage repair and response gene alterations and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma

Chicago, IL (OncToday.com) Recent introduction of PD/PDL1 immune checkpoint inhibitors (ICI) has redefined the treatment landscape of metastatic urothelial carcinoma. Different potential biomarkers of treatment responses have been proposed.
Read more ...

ASCO 2017: Unlocking the Genome: Insights Into Risk and Response in Bladder Cancer

Chicago, IL (OncToday.com) Dr. Bishoy Faltas from Weill Cornell Medical College concluded the Bladder Cancer Genomics session with a nice summary of the 4 abstracts presented today and his take on the current status of the field.
Read more ...

ASCO 2017: Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer

Chicago, IL (OncToday.com) Based on Level 1 evidence demonstrating cancer-specific survival benefit, neoadjuvant cisplatin-based chemotherapy (NAC) remains the standard of care for patients with muscle-invasive bladder urothelial cancer (MIBC). However, the 5-7% survival benefit along with the associated theoretical risk of treatment delay (in patients who don’t respond to NAC) and adverse events had led to significant underutilization. Better understanding of patient response to NAC will help guide potential adjunct therapy or alternative therapy.
Read more ...

ASCO 2017: Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response

Chicago, IL (OncToday.com) Immune-checkpoint blockade (ICB) continues to be the promising new therapeutic option for many advanced malignancies, including bladder urothelial cancer. With growing evidence for its use in advanced and metastatic urothelial carcinoma (UC), there is shifting emphasis on better patient selection.
Read more ...

ASCO 2017: Psychological Intervention Lowers Survivors’ Fear of Cancer Recurrence

Truckee, CA (OncToday.com) About 50% of all cancer survivors and 70% of young breast cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet, interventions to alleviate this fear are lacking. 
Read more ...
Page 2 of 4
@OncToday